Prognostic significance of tumor subtypes in male breast cancer: a population-based study

Substantial controversy exists about the prognostic role of tumor subtypes in male breast cancer (MaBC). The aim of this study was to analyze the characteristics of each tumor subtype in MaBC and its association with prognosis compared with other factors. We evaluated MaBC patients between 2010 and...

Full description

Saved in:
Bibliographic Details
Published in:Breast cancer research and treatment 2015-08, Vol.152 (3), p.601-609
Main Authors: Leone, José Pablo, Leone, Julieta, Zwenger, Ariel Osvaldo, Iturbe, Julián, Vallejo, Carlos Teodoro, Leone, Bernardo Amadeo
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Biomarkers, Tumor - metabolism
Breast cancer
Breast Neoplasms, Male - metabolism
Breast Neoplasms, Male - mortality
Breast Neoplasms, Male - pathology
Cancer
Cancer research
Cancer therapies
Comparative analysis
Epidemiology
Hormones, Sex
Humans
Kaplan-Meier Estimate
Male
Mastectomy
Medicine
Medicine & Public Health
Men
Middle Aged
Oncology
Oncology, Experimental
Prognosis
Receptor, ErbB-2 - metabolism
SEER Program
Studies
Survival Analysis
Triple Negative Breast Neoplasms - metabolism
Triple Negative Breast Neoplasms - mortality
Triple Negative Breast Neoplasms - pathology
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Substantial controversy exists about the prognostic role of tumor subtypes in male breast cancer (MaBC). The aim of this study was to analyze the characteristics of each tumor subtype in MaBC and its association with prognosis compared with other factors. We evaluated MaBC patients between 2010 and 2012 with known estrogen receptor, progesterone receptor [together hormone receptor (HR)] status, and human epidermal growth factor receptor 2 (HER2) status reported to the Surveillance, Epidemiology, and End Results program. Patients were classified as: HR-positive/HER2-negative, HR-positive/HER2-positive, HR-negative/HER2-positive, and triple-negative (TN). Univariate and multivariate analyses determined the effect of each variable on overall survival (OS). We included 960 patients. Patient distribution was 84.9 % HR-positive/HER2-negative, 11.6 % HR-positive/HER2-positive, 0.6 % HR-negative/HER2-positive, and 2.9 % TN. TN patients were younger, had higher grade, presented with more advanced stage, were more likely to have mastectomy, and to die of breast cancer (all P  
ISSN:0167-6806
1573-7217
DOI:10.1007/s10549-015-3488-y